Nebenwirkungen · Adcetris
ADCETRIS 50 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 20
HOS-126091 · Präparat HOS-096209
Safety was evaluated in an open-label, multicentre trial in 59 paediatric patients aged 6-17 years of age with previously untreated advanced-stage classical CD30+ HL in combination with chemotherapy (see section 5.1). In this study, no new safety concerns were reported. The most common serious adverse reaction reported in this study was febrile neutropenia (17%). G-CSF prophylaxis was considered at the physician’s discretion. Peripheral neuropathy events (per Standardized MedDRA Query) were reported in 24% of paediatric patients in this study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-20T10:51:00Z · SHA-256 a80608da289c54a95c6f3ae56a63c85084ccf90e8e43e395dd22479d252877cb · Passage bd6ce2cf2408687054dc276a9b8b32551e3900a89900e9f5b99cda4eac33f79a · Zeichen 19890–20439 im Abschnitt